AllNexImmune Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition Initial data demonstrate early signs of safety, tolerability and robust immune responses in acute myeloid…skylarbennethumDecember 7, 2020
3DBio TherapeuticsAll 3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients NEW YORK, Nov. 19, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for…skylarbennethumNovember 19, 2020
AllNexImmune NexImmune to Highlight Preliminary Results from Phase 1/2 Trial of NEXI-001 via Oral Presentation at 62nd ASH Annual Meeting GAITHERSBURG, Md., Nov. 04, 2020 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biotechnology company developing unique…skylarbennethumNovember 4, 2020
AllNexImmune NexImmune Establishes Research Initiative with City of Hope to Focus on Novel Immunotherapeutic Approaches to Acute Myeloid Leukemia City of Hope will combine its world-leading expertise with NexImmune technology to explore tumor escape…skylarbennethumOctober 27, 2020
AllAsclepix Therapeutics AsclepiX Therapeutics to Present at Solebury Trout Private Company Showcase on October 15, 2020 BALTIMORE, MD, October 13, 2020 – AsclepiX Therapeutics, Inc., a biopharmaceutical company that uses computational biology…skylarbennethumOctober 14, 2020
AllNexImmune First Patient Dosed in NexImmune Phase 1/2 Clinical Trial of NEXI-002 in Multiple Myeloma With the start of its second clinical trial, NexImmune expands development of its unique non-genetically…skylarbennethumOctober 6, 2020